Healthcare EBITDA Valuation Multiples & Arbitrage Dynamics
Deconstruct the valuation gap between 4x–7x solo tuck-ins and 12x–16x institutional platform recapitalizations through rigorous EBITDA normalization and revenue defense.
The primary economic thesis of healthcare private equity roll-ups is multiple arbitrage: acquiring fragmented, founder-led medical practices at 4x to 7x normalized EBITDA and exiting the unified, centralized MSO platform to secondary private equity sponsors or strategic health systems at 12x to 16x EBITDA. However, achieving this spread requires defensible EBITDA normalization. Solo practice financials are frequently distorted by discretionary owner expenses, non-market doctor compensation, underfunded clinical staff, and hidden coding liabilities. Kompanie LLP performs forensic valuation audits that establish bulletproof adjusted EBITDA benchmarks and protect acquirers from post-close margin collapse.
Deliverables
- Adjusted EBITDA normalization modeling adjusting for physician replacement compensation (FMV wRVU benchmarks).
- Working capital peg and net debt true-up mechanism calibration for healthcare seasonal claim cycles.
- Tiered rollover equity class modeling (Common Units vs Class B Incentive Units) maximizing doctor alignment.
- Downside valuation risk modeling quantifying impact of payer contract termination or physician departure.
Frequently asked questions
How is physician compensation normalized when calculating healthcare EBITDA?
Founding doctors often take all practice net profits as W-2 or K-1 distributions. Acquirers must replace this with a market-rate post-close compensation package—typically 30% to 35% of professional collections or an MGMA median per-wRVU rate ($65–$85/wRVU depending on specialty). The remaining cash flow represents true normalized EBITDA.
What specialties currently command the highest EBITDA multiples in 2026?
Cardiology, orthopedic surgery, dermatology, and medical oncology command peak platform valuations (12x–15x+) due to high procedural margins, in-office diagnostic ancillaries, and favorable demographic demand tailwinds.